EZH2 Expression in Liver Cancer
Author Information
Author(s): T. Sudo, T. Utsunomiya, K. Mimori, H. Nagahara, K. Ogawa, H. Inoue, S. Wakiyama, H. Fujita, K. Shirouzu, M. Mori
Primary Institution: Department of Surgery, Medical Institute of Bioregulation, Kyushu University
Hypothesis
The study investigates the relationship between EZH2 mRNA expression and clinicopathological features in patients with hepatocellular carcinoma (HCC).
Conclusion
EZH2 mRNA expression is upregulated in primary HCC tissues and is associated with a significantly increased incidence of portal vein invasion.
Supporting Evidence
- EZH2 expression was significantly higher in tumor tissues compared to nontumor tissues.
- 79% of patients in the high EZH2 expression group had portal vein invasion compared to 39% in the low expression group.
- No significant difference in disease-free survival rates was observed between high and low EZH2 expression groups.
Takeaway
This study found that a protein called EZH2 is more active in liver cancer, which might help doctors understand how aggressive the cancer is.
Methodology
Real-time reverse transcription–polymerase chain reaction was used to analyze EZH2 expression in tumor and nontumor tissue specimens.
Limitations
The study did not find significant differences in disease-free survival rates between high and low EZH2 expression groups.
Participant Demographics
66 patients with hepatocellular carcinoma who underwent surgery.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website